RECOMBIVAX HB

RECOMBIVAX HB is a vaccine used to prevent infection caused by all known subtypes of the hepatitis B virus.

The Hepatitis B vaccine products, such as Recombivax HB and Engerix-B, can be used interchangeably, despite having different antigen content. It is important to follow the recommended dose and schedule for the recipient’s age group as specified by the manufacturer.

The hepatitis B vaccine is recommended to prevent becoming infected with the hepatitis B virus, which can cause long-term liver damage and liver cancer. The virus is very contagious and can be spread through contact with blood and bodily fluids.

Heplisav-B and Engerix-B are both hepatitis B vaccines administered via intramuscular injection. However, Heplisav-B, which was approved in November 2017, contains an adjuvant that can enhance the immune response to the vaccine.

For individuals aged 20 years and above, a three-dose regimen is recommended for Recombivax HB. The first dose of 10mcg (1.0 mL) should be administered on the chosen date, followed by a second dose after one month and a third dose six months after the first dose. It is currently unknown how long the protective effect of Recombivax HB lasts in healthy individuals, and the necessity for booster doses has not been determined yet.

Recombivax HB, also known as Hepatitis B Vaccine, is approved for use in individuals of all ages. It is available under different brand names such as Energix B and Recombivax HB.

A booster, also known as revaccination, is an extra dose of the hepatitis B vaccine (HBV) administered after the initial vaccination to enhance immune memory and increase defense against the hepatitis B virus (HBV) infection.

There are three combination vaccines that include the HepB vaccine. The first one is called DTaP-HepB-IPV (Pediarix) and it is approved for children between the ages of 6 weeks and 6 years. The second one is called HepA-HepB (Twinrix) and it is approved for individuals who are 18 years or older. The third combination vaccine is called DTaP-IPV-Hib-HepB (Vaxelis) and it is licensed in the United States.

The vaccines vary in the concentration of the HBsAg antigen and the type of aluminum adjuvants used. Recombivax contains aluminum hydrophosphate sulphate, while Engerix-B utilizes aluminum hydroxide as an adjuvant and may contain trace amounts of thimerosal from the manufacturing process.

The vaccine does not contain live virus, so there is no risk of contracting hepatitis from it. Instead, it stimulates the body to produce antibodies that provide immunity against the hepatitis B virus, effectively preventing infection.

The overall efficacy of Heplisav-B (67.5%) is higher than the reported efficacy of Engerix-B (33-45%) in patients with chronic liver disease (CLD). Therefore, Heplisav-B is an effective hepatitis B vaccine for this patient population, especially for those with cirrhosis. However, more studies are required to evaluate the effectiveness of Heplisav-B in patients with CLD and after liver transplantation.

Heplisav-B and Engerix-B are both hepatitis B vaccines administered via intramuscular injection. However, Heplisav-B, which was approved in November 2017, contains an adjuvant that can enhance the immune response to the vaccine.

ENGERIX-B is a sterile suspension of noninfectious HBsAg designed for intramuscular administration. It is made from purified surface antigen of the hepatitis B virus, obtained through the culturing of genetically engineered Saccharomyces cerevisiae cells carrying the virus’s surface antigen gene.

The interchangeable use of Engerix-B or Recombivax-HB single antigen hepatitis B (1A-HepB) vaccines is well-established. However, there is limited data available on the safety and immunogenicity effects of interchanging doses of Heplisav-B (HepB-CpG) or PreHevbrio (3A-HepB) vaccines with HepB products from other manufacturers.

RECOMBIVAX HB is suitable for individuals of all age groups. However, the RECOMBIVAX HB Dialysis Formulation is specifically approved for use in adult predialysis and dialysis patients who are 18 years of age and older.

Recombivax HB Adult, a hepatitis B adult vaccine, belongs to the viral vaccines drug class and is typically used for preventing Hepatitis B. The price for a 10 milliliter supply of Recombivax HB Adult intramuscular suspension (10 mcg/mL) is approximately $712, but may vary depending on the pharmacy.

Both Paediatric® and Engerix-B Paediatric® vaccines can be used interchangeably, although it is not recommended to switch brands. Despite having different amounts of Hepatitis B surface Antigen, they are considered equivalent. Therefore, a 0.5mL injection is given regardless of which product is used.

The hepatitis B vaccine is administered in three doses. The first dose is given shortly after birth, the second dose is given one to two months later, and the third dose is given between 6 and 18 months of age.

Hepatitis B Vaccine Dosing Schedule:

– Children (1-10 years): 3 doses of 10 µg each, administered at 0, 1-2, and 6 months.
– Adolescents (11-19 years): 3 doses of 10 µg each, administered at 0, 1, and 6 months.
– Adults (20 years): 2 doses of 20 µg each.
– Patients on hemodialysis and other immune-compromised persons, <20 years: 2 doses of 10 µg each.

Engerix-B, Heplisav-B, and Recombivax HB are all FDA-approved hepatitis B vaccines. Engerix-B and Recombivax HB can be used in individuals of all ages.

Engerix B and Heplisav-B are both vaccines used for the prevention of hepatitis B. They have different dosing schedules and indications.

Engerix B is administered as a series of three doses. The first dose is given at the chosen date, followed by a second dose one month later, and a third dose six months after the first dose. It is indicated for individuals aged 20 years and younger, as well as for adults at high risk of hepatitis B infection, such as healthcare workers and individuals with chronic liver disease.

On the other hand, Heplisav-B is administered as a series of two doses. The first dose is given at the chosen date, followed by a second dose one month later. It is indicated for individuals aged 18 years and older.

Both vaccines are generally well-tolerated, with common adverse effects including pain at the injection site, fatigue, headache, and muscle aches. Serious allergic reactions are rare but can occur.

Engerix B and Heplisav-B may interact with certain medications, so it is important to inform your healthcare provider about all the medications you are taking before receiving the vaccine.

In conclusion, Engerix B and Heplisav-B are effective vaccines for the prevention of hepatitis B. They have different dosing schedules and indications, but both are generally safe and well-tolerated. It is important to discuss with your healthcare provider to determine which vaccine is appropriate for you.

Both ENGERIX-B and RECOMBIVAX HB can be used interchangeably at any dose, following the age-specific dosage and recommended schedule for each product. However, it is important to note that when using both products in a 2-dose series, there should be a minimum of 24 weeks between the first and second dose.

RECOMBIVAX HB is approved for the prevention of infection caused by all known subtypes of hepatitis B virus in individuals of all ages. The Dialysis Formulation is specifically approved for use in adult predialysis and dialysis patients 18 years of age and older.

Engerix-B, manufactured by GlaxoSmithKline, is a vaccine that requires three doses. However, it can also be administered on an accelerated schedule, with three shots given within a span of two months. Additionally, a booster dose is recommended after one year to ensure optimal long-term protection.

ENGERIX-B is a sterile, non-live vaccine for hepatitis B, free of thimerosal, and is intended for intramuscular injection. The vaccine is provided in a single-dose syringe containing hepatitis B surface antigen (HBsAg) adsorbed onto aluminum hydroxide (Al3+). It is available in both pediatric and adult doses.

Engerix B is a vaccine that is administered to prevent hepatitis B infection. Additionally, it has the capability to provide protection against hepatitis D infection. This vaccine is suitable for individuals who are 16 years of age and older, including both adults and adolescents. In certain situations, it may be administered to children and adolescents between the ages of 11 and 15 (refer to section 3 for more information).

The Hepatitis B vaccine products, such as Recombivax HB and Engerix-B, can be used interchangeably, despite having different antigen content. It is important to follow the recommended dose and schedule for the recipient’s age group as specified by the manufacturer.

The vaccine is administered in three doses, with the second dose given one month after the first dose, and the third dose given six months after the second dose.

In order to achieve full protection against hepatitis B, it is necessary to receive all doses of the vaccine. It is crucial to note that newborns born to infected mothers should receive the initial dose of the hepatitis B vaccine either in the delivery room or within the first 12 hours of their life. For more information on hepatitis B and pregnancy, please refer to the provided link.

The recommended schedule for hepatitis B vaccination is three intramuscular injections, with the second and third doses administered at 1 and 6 months, respectively, after the first dose. This schedule is commonly used for both children and adults.

Numerous studies have demonstrated that individuals, including infants, children, and adults, who have received a full series of hepatitis B immunization, remain protected from the disease for up to 15 years, even if their levels of protective antibodies decrease over time.

The vaccination schedule for individuals aged 20 and above receiving RECOMBIVAX HB consists of three doses, each measuring 1.0 mL. These doses are administered at intervals of 0 months, 1 month, and 6 months.

Upon completing the Twinrix® series, your immunity against hepatitis A is expected to last for a minimum of 20 years, while protection against hepatitis B is likely to be lifelong. To defend against germs, it is recommended to regularly wash your hands with soap and water for at least 15 seconds or use alcohol-based hand sanitizers.

To summarize, it has been found that a single dose of the HBV vaccine is insufficient to provide immunity for a period of five years. On the other hand, two doses of the HBV vaccine have been shown to be effective in producing immunity for five years. However, it is important to conduct HBsAb testing to confirm the presence of immunity.

To protect yourself as a healthcare worker, it is recommended by the CDC that you get vaccinated against hepatitis B if you are exposed to blood or bodily fluids on the job.

The hepatitis A vaccine is administered in two doses, with a minimum interval of six months between each dose. One dose provides a high level of protection against hepatitis A, while two doses offer complete protection, ensuring 100 percent effectiveness. It is important to note that these vaccines do not pose any risk of contracting hepatitis A or B.

If you are in good health, a booster dose of vaccine is typically not needed. However, it is advisable to consult with your doctor who can conduct a blood test to assess your immunity and determine if a booster dose is necessary.

Vaccine recommendations for individuals aged 19-26 years include:

– Hepatitis A (HepA): Depending on the specific vaccine, 2, 3, or 4 doses may be required.
– Hepatitis B (HepB): Depending on the specific vaccine, 2, 3, or 4 doses may be required.
– Meningococcal A, C, W, Y (MenACWY): Depending on the indication, 1 or 2 doses may be needed. Please refer to the notes for booster recommendations.
– Meningococcal B (MenB): No specific information provided.